Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Paolo Abrate"'
Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study
Autor:
Fiorenzo Santoleri, Paolo Abrate, Laura Pestrin, Enrico Pasut, Germana Modesti, Felice Musicco, Chiara Fulgenzio, Eva Zuzolo, Gabriella Pieri, Martina Roperti, Pietro Gazzola, Marco Gambera, Isabella Martignoni, Valentina Montresor, Francesca Guarino, Laura Grossi, Letizia Di Fabio, Cristina Roberti, Concetta Spoltore, Gabriella Tinari, Stefania De Rosa, Romina Giannini, Roberto Langella, Grazia Mingolla, Mariantonietta Piccoli, Alberto Costantini
Publikováno v:
Global & Regional Health Technology Assessment, Vol 11, Iss 1 (2024)
Introduction: This study aims to evaluate the persistence, treatment adherence and drug cost associated with biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the management of psoriatic arthritis (PsA) in Italy, w
Externí odkaz:
https://doaj.org/article/a5f5d14afc0945e59c39275f3305599a
Autor:
Felice Musicco, Ruggero Lasala, Fiorenzo Santoleri, Alberto Costantini, Paolo Abrate, Maria Teresa Carretta, Enrica Maria Proli, Alessia Romagnoli, Nicola Petragnani, Francesco De Vita, Massimo Zeuli, Patrizia Vici, Massimo Sansone, Matilde Pasquantonio, Antonia La Malfa, Chiara Fulgenzio
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
Objective Palbociclib, a highly selective reversible CDK4-6 kinase inhibitor, is indicated in combination with an aromatase inhibitor or in combination with fulvestrant in women who had received prior endocrine treatment. Studies have demonstrated th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e45a3aa7a60b8535c65f410cd565ec4a
https://pubmed.ncbi.nlm.nih.gov/35903919
https://pubmed.ncbi.nlm.nih.gov/35903919
Publikováno v:
Therapeutic innovationregulatory science.
To date, numerous biosimilars are available in Europe and the practice of switching between originator and biosimilar or between two different biosimilars has become very widespread. However, multiple switching has not been adequately studied. The ai
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15cc62fcfa78679bff7d6e50c4be1092
https://pubmed.ncbi.nlm.nih.gov/36322326
https://pubmed.ncbi.nlm.nih.gov/36322326
Available information about paediatric use of onco-haematological drugs authorized by EMA since 2016
Autor:
Alberto Costantini, Alessia Romagnoli, Felice Musicco, Paolo Abrate, Ruggero Lasala, Davide Zanon, Fiorenzo Santoleri
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 29(1)
Background The treatment options available to children with cancer are limited. This is why for more than 10 years, the European Medicine Agency (EMA) has stated that all drugs to be marketed must be tested on the paediatric population in accordance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63e8618adf38ca5362f668ec04f7e381
https://pubmed.ncbi.nlm.nih.gov/34693799
https://pubmed.ncbi.nlm.nih.gov/34693799
Autor:
Ruggero Lasala, Fiorenzo Santoleri, Alessia Romagnoli, Paolo Abrate, Felice Musicco, Alberto Costantini
Publikováno v:
European journal of hospital pharmacy : science and practice.
To assess how and to what extent adherence to medication is reported in pivotal clinical trials of oral cancer drugs.All drugs authorised by the European Medicines Agency from 1 January 2014 to 31 December 2019 were considered for analysis. For each
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fbd4693a0ffc179522ac693c5fbccb1c
https://pubmed.ncbi.nlm.nih.gov/35058307
https://pubmed.ncbi.nlm.nih.gov/35058307
Autor:
Paolo Abrate, Felice Musicco, Alessia Romagnoli, Ruggero Lasala, Alberto Costantini, Fiorenzo Santoleri
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(4)
Introduction Pivotal Randomized Controlled Trials (RCTs) constitute scientific evidence in support of therapeutic choices when a drug is authorized in the market. In RCTs, patients are selected in a rigorous manner, in order to avoid bias that may in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f1b9b2efff869dddfab614393ae3d706
https://pubmed.ncbi.nlm.nih.gov/33847190
https://pubmed.ncbi.nlm.nih.gov/33847190